🇪🇺 valsartan/amlodipine in European Union

EMA authorised valsartan/amlodipine on 16 January 2007

Marketing authorisation

EMA — authorised 16 January 2007

  • Application: EMEA/H/C/000716
  • Marketing authorisation holder: Novartis Europharm Limited
  • Local brand name: Exforge
  • Indication: Treatment of essential hypertension. Exforge is indicated in patients whose blood pressure is not adequately controlled on amlodipine or valsartan monotherapy.
  • Status: approved

Read official source →

Other Cardiovascular approved in European Union

Frequently asked questions

Is valsartan/amlodipine approved in European Union?

Yes. EMA authorised it on 16 January 2007.

Who is the marketing authorisation holder for valsartan/amlodipine in European Union?

Novartis Europharm Limited holds the EU marketing authorisation.